Skip to main content
SpringerLink
Log in

Improvement in Treatment and Outcome of Pancreatic Ductal Adenocarcinoma in North China

  • Original Article
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Background

The incidence of pancreatic cancer has increased in China in the last decade, though efforts have been made in early detection and multimodality treatment. The aim of this study is to describe the decade-based development in early diagnosis and treatment modalities, as well as outcome for patients with pancreatic ductal adenocarcinoma (PDAC) in a high-volume facility.

Methods

All the PDAC patients underwent surgery between 1991 and 2009 and were selected from the database of TianJin Cancer Institute and Hospital. Decade-based changes in early diagnosis, treatment modalities, and outcome of the patients were retrospectively analyzed.

Results

Of the 565 patients with PDAC, patients in this decade (n = 460) had better overall survival than those in the last decade (n = 105), median survival was 10 months and 3 months, respectively. Patients in this decade had significantly improved in (P < 0.001) 2-year (14.7%) and 5-year survival rates (3.5%) as compared to those in the last decade (6.7% and 3.4%, respectively). Patients with metastasis at diagnosis in the last decade and this decade were 54% and 26% (P < 0.001), respectively. More patients in this decade had underwent R0/R1 resection (33% vs 20%, P = 0.010), chemotherapy (37% vs 12%, P < 0.001), and radical resection (34% vs 21%, P = 0.014) than those in the last decade.

Conclusion

Patients operated on for PDAC in this decade had a better outcome than those in the last decade. Early detection, improved resection margin, and development in multimodality treatment contribute to this improvement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Song F, He M, Hao XS et al. (2008) A cancer incidence survey in Tianjin: the third largest city in China-between 1981 and 2000. Cancer Causes Control 19(5): 443–450.

    Article  PubMed  Google Scholar 

  2. Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Lüttges J, Klöppel G, Haglund C. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005;54(3):385–387.

    Article  PubMed  CAS  Google Scholar 

  3. Parkin DM: International variation. Oncogene 2004;23:6329–6340.

    Article  PubMed  CAS  Google Scholar 

  4. Kleeff J, Michalski C, Friess H, Büchler MW. Pancreatic cancer: from bench to 5-year survival. Pancreas 2006;33(2):111–118.

    Article  PubMed  CAS  Google Scholar 

  5. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C and Neoptolemos JP. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 1995;82(1):111–115.

    Article  PubMed  CAS  Google Scholar 

  6. Niederhuber JE, Brennan MF, Menck HR. The national cancer data base report on pancreatic cancer. Cancer 1995;76(9):1671–1677.

    Article  PubMed  CAS  Google Scholar 

  7. Buchler MW, Wagner M, Schmied BM, Uhl W, Friess H and Z’graggen K. Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg 2003;138(12): 1310–1314.

    Article  PubMed  Google Scholar 

  8. Cameron JL, Taylor SR, Coleman JA, Belcheret KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006;244(1): 10–15.

    Article  PubMed  Google Scholar 

  9. Winter JM, Cameron JL, Campbell KA et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006;10(9):1199–1210.

    Article  PubMed  Google Scholar 

  10. Neoptolemos J, Stocken D, Freiss H et al. A randomised trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–1210.

    Article  PubMed  CAS  Google Scholar 

  11. Neuhaus P, Riess H, Post S et al. (2008) CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol 26 (May 20 suppl) (abstr LBA4504).

  12. Li Q, Gao C, Li H, Juzi JT, Chen H, Hao X. Factors Associated with Survival after Surgical Resection in Chinese Patients with Ductal Adenocarcinoma of the Pancreatic Head. Dig Surg 2008;25:87–92.

    Article  PubMed  Google Scholar 

  13. Greene FL, Compton CC, Fritz AG, Shan JP, Winchester DP (2002) American Joint Committee on Cancer, American Cancer Society. AJCC Cancer staging handbook: from the AJCC cancer staging manual 6th edition. Springer, New York

    Google Scholar 

  14. Kloppel G, Hruban RH, Longnecker DS. Ductal adenocarcinoma of the pancreas. In SR Hamilton, LA Aaltonen, (eds.) WHO Classification of Tumors: Pathology and Genetics of Tumors of the Digestive System. Lyon: IARC Press, 2000, pp221–230.

    Google Scholar 

  15. Sobin LH, Gospodarowicz MK, Wittekind C. Digestive system tumors. TNM Classification of malignant tumours. Wiley-Liss, New York, 2009, pp132–135.

    Google Scholar 

  16. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.

    Article  Google Scholar 

  17. Cox DR: Regression models and life-tables. J R Stat Soc B 1972; 34:187–220.

    Google Scholar 

  18. Millikan KW, Deziel DJ, Silverstein JC, Kanjo TM, Christein JD, Doolas A, Prinz RA. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 1999;65:618–623.

    PubMed  CAS  Google Scholar 

  19. Park SJ, Kim SW, Jang JY, Lee KU, Park YH. Intraoperative transfusion: is it a real prognostic factor of periampullary cancer following pancreatoduodenectomy? World J Surg 2002; 26:487–492.

    Article  PubMed  Google Scholar 

  20. Yeh JJ, Gonen M, Tomlinson JS, Idrees K, Brennan MF, Fong Y. Effect of blood transfusion on outcome after pancreaticoduodenectomy for exocrine tumour of the pancreas. Br J Surg 2007;94:466–472.

    Article  PubMed  CAS  Google Scholar 

  21. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Michael JT. Cancer statistics, 2003. CA Cancer J Clin 2003;53(1):5–26.

    Article  PubMed  Google Scholar 

  22. Esteller M, Hamilton SR, Burger PC, Baylin SB and Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59 (4):793–797.

    PubMed  CAS  Google Scholar 

  23. Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 2002;16(1):37–52.

    Article  PubMed  Google Scholar 

  24. Tumour markers in gastrointestinal cancers—EGTM recommendations. European Group on Tumour Markers. Anticancer Res 1999;19 (4A):2811–2815.

    Google Scholar 

  25. AM Lennon, M Goggins (2010) Diagnostic and Therapeutic Response Markers. In: JP Neoptolemos, R Urrutia, JL Abbruzzese, MW Büchler. Pancreatic Cancer. Springer, New York; 676–691.

  26. Kuhlmann KF, de Castro SM, Wesseling JG, et al. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004;40(4):549–558.

    Article  PubMed  CAS  Google Scholar 

  27. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234(6):758–68.

    Article  PubMed  CAS  Google Scholar 

  28. Kato K, Yamada S, Sugimoto H, et al. Prognostic factors for survival after extended pancreatectomy for pancreatic head cancer: influence of resection margin status on survival. Pancreas 2009;38(6):605–12.

    Article  PubMed  Google Scholar 

  29. Fatima J, Schnelldorfer T, Barton J, et al. Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg. 2010;145:167–72.

    Article  PubMed  Google Scholar 

  30. Amano H, Miura F, Toyota N, et al. Is pancreatectomy with arterial reconstruction a safe and useful procedure for locally advanced pancreatic cancer? J Hepatobiliary Pancreat Surg. 2009;16(6):850–7.

    Article  PubMed  Google Scholar 

  31. Shimada K, Sano T, Sakamoto Y, Kosuge T. Clinical implications of combined portal vein resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma. Ann Surg Oncol. 2006;13:1569–1578.

    Article  PubMed  Google Scholar 

  32. Shaib Y, Davila J, Naumann C, El-Serag H. The impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. Population-based study. Am J Gastroenterol. 2007;102:1377–1382.

    Article  PubMed  Google Scholar 

  33. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Büchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004;91:586–594.

    Article  PubMed  CAS  Google Scholar 

  34. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006;13(8):1035–1046.

    Article  PubMed  Google Scholar 

  35. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: The importance of this emerging stage of disease. J Am Coll Surg 2008;206(5):833–846.

    Article  PubMed  Google Scholar 

  36. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997;21:195–200.

    Article  PubMed  CAS  Google Scholar 

  37. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 2006;10: 511–518.

    Article  PubMed  Google Scholar 

  38. Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15 (6):2403–2413.

    PubMed  CAS  Google Scholar 

  39. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321(5897):1801–1806.

    Article  PubMed  CAS  Google Scholar 

  40. Wong HH, Lemoine NR. Biological approaches to therapy of pancreatic cancer. Pancreatology 2008; 8:431–461.

    Article  PubMed  Google Scholar 

  41. Gjertsen MK, Buanes T, Rosseland AR, et al. Intradermal ras peptide vaccination with granulocytemacrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001;92:441–450.

    Article  PubMed  CAS  Google Scholar 

  42. Toubaji A, Achtar M, Provenzano M, et al. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother 2008;57:1413–1420.

    Article  PubMed  CAS  Google Scholar 

  43. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960–1966.

    Article  PubMed  CAS  Google Scholar 

  44. Melisi D, Ishiyama S, Sclabas GM, et al. LY2109761, a novel transforming growth factor b receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 2008;7:829–840.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Dr. FengJu Song from the Department of Epidemiology for statistical assistance.

Author information

Authors and Affiliations

  1. Key Laboratory of Cancer Prevention and Therapy, Huanhu Xi road, Hexi district, Tianjin, 300060, China

    Yong Chen & XiShan Hao

  2. Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China

    JiHui Hao, WeiDong Ma, Yong Tang & ChunTao Gao

Authors
  1. Yong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. JiHui Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. WeiDong Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yong Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. ChunTao Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. XiShan Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to XiShan Hao.

Additional information

JiHui Hao contributed equally with Yong Chen.

Grant support

National Natural Science Foundation of China (30701013, 30900596, 30973490, 30901448).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, Y., Hao, J., Ma, W. et al. Improvement in Treatment and Outcome of Pancreatic Ductal Adenocarcinoma in North China. J Gastrointest Surg 15, 1026–1034 (2011). https://doi.org/10.1007/s11605-011-1493-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-011-1493-y

Keywords

Search

Navigation